Investor profile
M13
VC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
M13 is an early-stage venture capital firm that invests in visionary founders building disruptive software businesses. The firm acts as a 'full-stack partner,' pairing capital with a deep bench of full-time operators to help founders shortcut the learning curve, scale efficiently, and build category-defining companies. M13 focuses on infrastructure technologies—particularly AI and web3—that power the future of work, health, commerce, and money, targeting 20% ownership stakes and 30–35 core investments per fund structured around power-law outcomes.
Notable quotes
“We've shown repeatability with two top-performing funds. The only reason this fund is larger is that we believe our model around propulsion—this large operating team we have that works with our portfolio companies—is fundamentally impacting the companies that we invest in by helping them scale faster.”
“People think of us as great DTC investors but they miss the point. The job of a VC is to understand the latest innovations that will change the world.”
“Morgan Blumberg is a partner at M13 known for a contrarian thesis on agentic workflow automation. She invests in AI that replaces painful back office work in healthcare and enterprise.”
Team
Courtney Reum
Co-Founder & Partner
Latif Peracha
General Partner
Morgan Blumberg
Partner
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Jimini Health | Seed | — | 2026-03-31 |
| OpenFX | Seed | — | 2026-03-31 |
| Luminos.AI | Seed | — | 2026-02-24 |
| Maven AGI | Series A | — | 2024-01-01 |
| Niural AI | Seed | — | 2024-01-01 |
| Ring | Seed | — | 2016-01-01 |
| Lyft | Series A | — | 2016-01-01 |
| Series A | — | 2016-01-01 | |
| Daily Harvest | Seed | — | 2017-01-01 |
| Matterport | Series A | — | 2018-01-01 |
Frequent co-investors
Fit check
Is M13 a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit